With added push from the COVID-19 pandemic, investment in promising RNA- and cell and gene therapy-based treatments and technology via industry dealmaking is growing considerably.
Mike Ward
Advertisement
Global Head of Thought Leadership, Decision Resources Group, Clarivate
Articles by Mike Ward
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Novo Nordisk's Shares Fall After Board Shake-Up
2
Alkermes plc Acquiring Avadel Pharmaceuticals in $2.1 Billion Definitive Agreement
3
Roundup: Pharma Industry Raises Funding Aimed at Advancing the Development and Testing of Rare Disease Treatments
4
Moderna Ceases Development of mRNA-1647 After Failing to Reach Primary Goal in Clinical Trial
5
